Specialty Pharmacies

XALKORI® (crizotinib) is available through specific specialty pharmacies
To help patients access the medication you’ve prescribed, Pfizer Oncology Together™ can identify specialty pharmacy options. If you prefer, you and your staff can also continue to work directly with specialty pharmacies.
Contact the specialty pharmacy directly to fill the prescription if one of the following applies:
  • Your office knows the patient’s specialty pharmacy
  • Your patient knows that the specialty pharmacy is covered in his/her plan and that the pharmacy is in the treatment network
  • Your office uses a specialty pharmacy that is in the patient’s network
Specialty pharmacy ordering process
The provider’s office:
  • Submits prescriptions to the specialty pharmacy via phone, fax, or online
  • Submits any supporting documentation to the payer
The specialty pharmacy:
  • Verifies the patient’s coverage
  • Helps with prior authorization if required
  • Can help patients seek co-pay assistance
  • Schedules shipment of product to the patient’s home
  • Bills the payer for the cost of the product
  • Bills the patient for remaining co-pay/coinsurance
Visit PfizerOncologyTogether.com to see the complete list of specialty pharmacies in the XALKORI distribution network.
*Preferred interventions are based on efficacy, safety, and evidence. Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate. Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate. All NCCN recommendations are category 2A unless otherwise indicated.
The NCCN Guidelines® for NSCLC provide recommendations for individual biomarkers that should be tested and recommend testing techniques but do not endorse any specific commercially available biomarker assays.
REFERENCE
  1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer V.3.2019. © National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed January 18, 2019. To view the most recent and complete version of the guideline, go online to NCCN.org. The National Comprehensive Cancer Network makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.